

Express Mail EV 330856466 US
Mailed August 4, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HARRIS et al.

Application No.: Not Yet Assigned

Filed: August 4, 2003

For: SCREENING ASSAYS FOR
COMPOUNDS THAT CAUSE
APOPTOSIS

Customer No.: 20350

Confirmation No.: Not Yet Assigned

Examiner: Not Yet Assigned

Technology Center/Art Unit: Not Yet
Assigned

REQUEST TO ACCEPT IN THE
PRESENT CASE THE SEQUENCE
LISTING FILED IN THE PARENT CASE

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants have previously filed on October 28, 1996 a sequence listing and accompanying computer readable diskette in the parent Application No. 08/359,316. Applicants request the use of the previously filed diskette containing the sequence information in computer readable form in the parent application in lieu of providing a diskette herewith. The diskette submitted to the USPTO in the parent application on October 28, 1996 is the only computer-readable form filed. The parent application information data is as follows:

Applicants: Harris et al.
Serial No. 08/359,316
Filed: December 19, 1994
Title: SCREENING ASSAYS FOR COMPOUNDS THAT CAUSE APOPTOSIS

Express Mail EV 330856466 US

Mailed August 4, 2003

As required by 1.821(f), applicants state that the content of the above-identified computer readable diskette submitted in the parent application is the same as the content of the hard copy of the Sequence Listing (pages 37-43) submitted to the USPTO in the parent application and herewith in the accompanying divisional application.

Respectfully submitted,



Kenneth A. Weber

Reg. No. 31,677

TOWNSEND and TOWNSEND and CREW LLP

Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834

Tel: 415-576-0200

Fax: 415-576-0300

Attachments

KAW:dk

60010106 v1

Transmittal Sheet

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center
Eight Floor
San Francisco, CA 94111-3834
(415) 576-0200
(415) 576-0300 FAX

Atty. Docket No. 15280-225000

Date October 28, 1996

In re application of:

Curtis C. Harris et al.

Serial No.: 08/359,316

Filed: December 19, 1994

Group Art Unit: 1811

For: SCREENING ASSAYS FOR
COMPOUNDS THAT CAUSE
APOPTOSIS

I hereby certify that this is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents
Washington, D. C. 20231.

Date: October 28, 1996

Sherry Barton

THE ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Sir:

Transmitted herewith for the above-identified application are:

- [X] Petition to Extend Time [CFR § 1.136(a)] with fee authorization \$110.00
- [X] Declaration with Exhibits 1-4 [CFR § 1.131]
- [X] Amendment [37 CFR § 1.115]
- [X] Substitute Paper Copy and Computer Readable Form of Sequence Listing [37 C.F.R. §§ 1.821-1.825]
- [X] Fee

☐ No fee is due.

Please charge Deposit Account No. 20-1430 as follows:

☒ Any additional fees associated with this paper or during the pendency of this application.

Two copies of this sheet are enclosed.

TOWNSEND and TOWNSEND and CREW LLP

Kenneth A. Weber
Kenneth A. Weber
Reg. No.: 31,677
Attorneys for Applicants

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: HARRIS, Curtis C.
WANG, Xin Wei
HOEIJMAKERS, Jan H.J.
- (ii) TITLE OF INVENTION: SCREENING ASSAYS FOR COMPOUNDS THAT
CAUSE APOPTOSIS
- (iii) NUMBER OF SEQUENCES: 6
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Townsend and Townsend Khourie and Crew
 - (B) STREET: Steuart Street Tower, One Market Plaza
 - (C) CITY: San Francisco
 - (D) STATE: California
 - (E) COUNTRY: US
 - (F) ZIP: 94105-1493
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: US not yet designated
 - (B) FILING DATE: 19-DEC-1994
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Kruse, Norman J.
 - (B) REGISTRATION NUMBER: 35,235
 - (C) REFERENCE/DOCKET NO: 15280-225000
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (415) 543-9600
 - (B) TELEFAX: (415) 543-5043

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 393 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (ix) FEATURE:
 - (A) NAME/KEY: Protein
 - (B) LOCATION: 1..393
 - (D) OTHER INFORMATION: /note= "Amino acid sequence of human wild-type p53."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

Met Glu Glu Pro Gln Ser Asp Pro Ser Val Glu Pro Pro Leu Ser Gln
1      5      10      15

Glu Thr Phe Ser Asp Leu Trp Lys Leu Leu Pro Glu Asn Asn Val Leu
20     25     30

Ser Pro Leu Pro Ser Gln Ala Met Asp Asp Leu Met Leu Ser Pro Asp
35     40     45

Asp Ile Glu Gln Trp Phe Thr Glu Asp Pro Gly Pro Asp Glu Ala Pro
50     55     60

Arg Met Pro Glu Ala Ala Pro Arg Val Ala Pro Gly Pro Ala Ala Pro
65     70     75     80

Thr Pro Ala Ala Pro Ala Pro Ala Pro Ser Trp Pro Leu Ser Ser Ser
85     90     95

Val Pro Ser Gln Lys Thr Tyr Gln Gly Ser Tyr Gly Phe Arg Leu Gly
100    105    110

Phe Leu His Ser Gly Thr Ala Lys Ser Val Thr Cys Thr Tyr Ser Pro
115    120    125

Ala Leu Asn Lys Met Phe Cys Gln Leu Ala Lys Thr Cys Pro Val Gln
130    135    140

Leu Trp Val Asp Ser Thr Pro Pro Pro Gly Thr Arg Val Arg Ala Met
145    150    155    160

Ala Ile Tyr Lys Gln Ser Gln His Met Thr Glu Val Val Arg Arg Cys
165    170    175

Pro His His Glu Arg Cys Ser Asp Ser Asp Gly Leu Ala Pro Pro Gln
180    185    190

His Leu Ile Arg Val Glu Gly Asn Leu Arg Val Glu Tyr Leu Asp Asp
195    200    205

Arg Asn Thr Phe Arg His Ser Val Val Val Pro Tyr Glu Pro Pro Glu
210    215    220

Val Gly Ser Asp Cys Thr Thr Ile His Tyr Asn Tyr Met Cys Asn Ser
225    230    235    240

Ser Cys Met Gly Gly Met Asn Arg Arg Pro Ile Leu Thr Ile Ile Thr
245    250    255

```

Leu Glu Asp Ser Ser Gly Asn Leu Leu Gly Arg Asn Ser Phe Glu Val
 260 265 270
 Arg Val Cys Ala Cys Pro Gly Arg Asp Arg Arg Thr Glu Glu Glu Asn
 275 280 285
 Leu Arg Lys Lys Gly Glu Pro His His Glu Leu Pro Pro Gly Ser Thr
 290 295 300
 Lys Arg Ala Leu Pro Asn Asn Thr Ser Ser Ser Pro Gln Pro Lys Lys
 305 310 315 320
 Lys Pro Leu Asp Gly Glu Tyr Phe Thr Leu Gln Ile Arg Gly Arg Glu
 325 330 335
 Arg Phe Glu Met Phe Arg Glu Leu Asn Glu Ala Leu Glu Leu Lys Asp
 340 345 350
 Ala Gln Ala Gly Lys Glu Pro Gly Gly Ser Arg Ala His Ser Ser His
 355 360 365
 Leu Lys Ser Lys Lys Gly Gln Ser Thr Ser Arg His Lys Lys Leu Met
 370 375 380
 Phe Lys Thr Glu Gly Pro Asp Ser Asp
 385 390

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1..19
- (D) OTHER INFORMATION: /note= "Peptide # p53cp: amino acid sequence of p53 peptide."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Ser His Leu Lys Ser Lys Lys Gly Gly Ser Thr Ser Arg His Lys Lys
 1 5 10 15
 Leu Met Phe

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 781 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens

(ix) FEATURE:
 (A) NAME/KEY: Protein
 (B) LOCATION: 1..781
 (D) OTHER INFORMATION: /note= "Amino acid sequence of human XPB."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

Met Gly Lys Arg Asp Arg Ala Asp Arg Asp Lys Lys Lys Ser Arg Lys
1           5           10
Arg His Tyr Glu Asp Glu Glu Asp Asp Glu Glu Asp Ala Pro Gly Asn
20          25          30
Asp Pro Gln Glu Ala Val Pro Ser Ala Ala Gly Lys Gln Val Asp Glu
35          40          45
Ser Gly Thr Lys Val Asp Glu Tyr Gly Ala Lys Asp Tyr Arg Leu Gln
50          55          60
Met Pro Leu Lys Asp Asp His Thr Ser Arg Pro Leu Trp Val Ala Pro
65          70          75          80
Asp Gly His Ile Phe Leu Glu Ala Phe Ser Pro Val Tyr Lys Tyr Ala
85          90          95
Gln Asp Phe Leu Val Ala Ile Ala Glu Pro Val Cys Arg Pro Thr His
100         105         110
Val His Glu Tyr Lys Leu Thr Ala Tyr Ser Leu Tyr Ala Ala Val Ser
115        120        125
Val Gly Leu Gln Thr Ser Asp Ile Thr Glu Tyr Leu Arg Lys Leu Ser
130        135        140
Lys Thr Gly Val Pro Asp Gly Ile Met Gln Phe Ile Lys Leu Cys Thr
145        150        155        160
Val Ser Tyr Gly Lys Val Lys Leu Val Leu Lys His Asn Arg Tyr Phe
165        170        175
Val Glu Ser Cys His Pro Asp Val Ile Gln His Leu Leu Gln Asp Pro
180        185        190
Val Ile Arg Glu Cys Arg Leu Arg Asn Ser Glu Gly Glu Ala Thr Glu
195        200        205
Leu Ile Thr Glu Thr Phe Thr Ser Lys Ser Ala Ile Ser Lys Thr Ala
210        215        220
Glu Ser Ser Gly Gly Pro Ser Thr Ser Arg Val Thr Asp Pro Gln Gly
225        230        235        240
Lys Ser Asp Ile Pro Met Asp Leu Phe Asp Phe Tyr Glu Gln Met Asp
245        250        255

```

Lys Asp Glu Glu Glu Glu Glu Glu Thr Gln Thr Val Ser Phe Glu Val
 260 265 270
 Lys Gln Glu Met Ile Glu Glu Leu Gln Lys Arg Cys Ile His Leu Glu
 275 280 285
 Tyr Pro Leu Leu Ala Glu Tyr Asp Phe Arg Asn Asp Ser Val Asn Pro
 290 295 300
 Asp Ile Asn Ile Asp Leu Lys Pro Thr Ala Val Leu Arg Pro Tyr Gln
 305 310 315 320
 Glu Lys Ser Leu Arg Lys Met Phe Gly Asn Gly Arg Ala Arg Ser Gly
 325 330 335
 Val Ile Val Leu Pro Cys Gly Ala Gly Lys Ser Leu Val Gly Val Thr
 340 345 350
 Ala Ala Cys Thr Val Arg Lys Arg Cys Leu Val Leu Gly Asn Ser Ala
 355 360 365
 Val Ser Val Glu Gln Trp Lys Ala Gln Phe Lys Met Trp Ser Thr Ile
 370 375 380
 Asp Asp Ser Gln Ile Cys Arg Phe Thr Ser Asp Ala Lys Asp Lys Pro
 385 390 395 400
 Ile Gly Cys Ser Val Ala Ile Ser Thr Tyr Ser Met Leu Gly His Thr
 405 410 415
 Thr Lys Arg Ser Trp Glu Ala Glu Arg Val Met Glu Trp Leu Lys Thr
 420 425 430
 Gln Glu Trp Gly Leu Met Ile Leu Asp Glu Val His Thr Ile Pro Ala
 435 440 445
 Lys Met Phe Arg Arg Val Leu Thr Ile Val Gln Ala His Cys Lys Leu
 450 455 460
 Gly Leu Thr Ala Thr Leu Val Arg Glu Asp Asp Lys Ile Val Asp Leu
 465 470 475 480
 Asn Phe Leu Ile Gly Pro Lys Leu Tyr Glu Ala Asn Trp Met Glu Leu
 485 490 495
 Gln Asn Asn Gly Tyr Ile Ala Lys Val Gln Cys Ala Glu Val Trp Cys
 500 505 510
 Pro Met Ser Pro Glu Phe Tyr Arg Glu Tyr Val Ala Ile Lys Thr Lys
 515 520 525
 Lys Arg Ile Leu Leu Tyr Thr Met Asn Pro Asn Lys Phe Arg Ala Cys
 530 535 540
 Gln Phe Leu Ile Lys Phe His Glu Arg Arg Asn Asp Lys Ile Ile Val
 545 550 555 560
 Phe Ala Asp Asn Val Phe Ala Leu Lys Glu Tyr Ala Ile Arg Leu Asn
 565 570 575
 Lys Pro Tyr Ile Tyr Gly Pro Thr Ser Gln Gly Glu Arg Met Gln Ile
 580 585 590


```

Leu Gln Asn Phe Lys His Asn Pro Lys Ile Asn Thr Ile Phe Ile Ser
    595                                600                                605

Lys Val Gly Asp Thr Ser Phe Asp Leu Pro Glu Ala Asn Val Leu Ile
    610                                615                                620

Gln Ile Ser Ser His Gly Gly Ser Arg Arg Gln Glu Ala Gln Arg Leu
    625                                630                                635                                640

Gly Arg Val Leu Arg Ala Lys Lys Gly Met Val Ala Glu Glu Tyr Asn
    645                                650                                655

Ala Phe Phe Tyr Ser Leu Val Ser Gln Asp Thr Gln Glu Met Ala Tyr
    660                                665                                670

Ser Thr Lys Arg Gln Arg Phe Leu Val Gln Gly Tyr Ser Phe Lys Val
    675                                680                                685

Ile Thr Lys Leu Ala Gly Met Glu Glu Glu Asp Leu Ala Phe Ser Thr
    690                                695                                700

Lys Glu Glu Gln Gln Gln Leu Leu Gln Lys Val Leu Ala Ala Thr Asp
    705                                710                                715                                720

Leu Asp Ala Glu Glu Glu Val Val Ala Gly Glu Phe Gly Ser Arg Ser
    725                                730                                735

Ser Gln Ala Ser Arg Arg Phe Gly Thr Met Ser Ser Met Ser Gly Ala
    740                                745                                750

Asp Asp Thr Val Tyr Met Glu Tyr His Ser Ser Arg Ser Lys Ala Pro
    755                                760                                765

Ser Lys His Val His Pro Leu Phe Lys Arg Phe Arg Lys
    770                                775                                780

```

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 15 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(ix) FEATURE:

- (A) NAME/KEY: Peptide
- (B) LOCATION: 1..15
- (D) OTHER INFORMATION: /note= "Peptide # 464: XPB peptide that binds wild-type p53 protein."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

```

Leu Gly Leu Thr Ala Thr Leu Val Arg Glu Asp Asp Lys Ile Val
1           5           10           15

```

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 15 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (ix) FEATURE:
 - (A) NAME/KEY: Peptide
 - (B) LOCATION: 1..15
 - (D) OTHER INFORMATION: /note= "Peptide # 479: XPB peptide that does not bind wild-type p53 protein."
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Leu | Asn | Phe | Leu | Ile | Gly | Pro | Lys | Leu | Tyr | Glu | Ala | Asn | Trp |
| 1 | | | | 5 | | | | | 10 | | | | | 15 |

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 16 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (ix) FEATURE:
 - (A) NAME/KEY: Peptide
 - (B) LOCATION: 1..16
 - (D) OTHER INFORMATION: /note= "Peptide # 99: control peptide."
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Leu | Ser | Ala | Met | Ser | Thr | Thr | Asp | Leu | Glu | Ala | Tyr | Phe | Lys | Asp |
| 1 | | | | 5 | | | | 10 | | | | | | 15 | |